<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1859">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136963</url>
  </required_header>
  <id_info>
    <org_study_id>19CH047</org_study_id>
    <secondary_id>2020-000853-29</secondary_id>
    <nct_id>NCT05136963</nct_id>
  </id_info>
  <brief_title>Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance</brief_title>
  <acronym>CLIO</acronym>
  <official_title>Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance Using Limited Sample Strategy for the Evaluation of Kidney Donation Candidates.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In kidney transplantation, donor selection is based in part on the assessment of the&#xD;
      functional capacity of the kidneys. For this purpose, it is recommended to measure the&#xD;
      glomerular filtration rate (GFR) by a reference technique. To estimate GFR, several&#xD;
      approaches are possible depending on the type of measurement (urinary or plasma) and the&#xD;
      marker (exogenous or endogenous) used. Among these methods, the measurement of inulin&#xD;
      clearance has long been considered the reference method. The occurrence of anaphylactic&#xD;
      reactions led to its withdrawal from the market. Iohexol, an iodinated contrast agent, has&#xD;
      characteristics similar to inulin. It is eliminated by glomerular filtration and its&#xD;
      biological determination is simple.&#xD;
&#xD;
      Nevertheless, the techniques currently used to calculate plasma clearance of Iohexol have&#xD;
      been imperfectly validated and are not always easy to implement in practice. the&#xD;
      investigators propose to develop a Bayesian estimator for estimating Iohexol clearance&#xD;
      applied to a population of healthy subjects, representative of potential kidney donors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2022</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Iohexol pharmacokinetic calculated with Bayesian estimator and with classic method</measure>
    <time_frame>Hours: 0h30, 1h00, 1h30, 02h00, 03h00, 04h00, 05h00, 06h00, 09h00, 12h00 after Iohexol administration</time_frame>
    <description>Clearance of Iohexol calculated with Bayesian estimator (limited samples) and with classic method (rich samples).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Iohexol pharmacokinetic calculated with Bayesian estimator and Brochner-Mortensen method</measure>
    <time_frame>Hours: 0h30, 1h00, 1h30, 02h00, 03h00, 04h00, 05h00, 06h00, 09h00, 12h00 after Iohexol administration</time_frame>
    <description>Clearance of Iohexol calculated with Bayesian estimator (limited samples) and Brochner-Mortensen method (5 samples).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Kidney Function Test</condition>
  <arm_group>
    <arm_group_label>volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48 volunteers will be included according to the following demographic characteristics (corresponding to the demographic profile of kidney donors according to the national data of the Biomedicine Agency):&#xD;
aged between 20 and 35 years old: 4 women, 3 men&#xD;
aged between 35 and 50 years old: 7 women, 5 men&#xD;
aged between 50 and 65: 11 women, 8 men&#xD;
&gt; 65 years old: 6 women, 4 men</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>5 milliliter of iohexol will be administrated.</description>
    <arm_group_label>volunteers</arm_group_label>
    <other_name>Omnipaque</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pharmacokinetics</intervention_name>
    <description>10 blood samples of 5 milliliter will be performed. sampling time ater administration of Iohexol: 00h30, 1h00, 1h30, 02h00, 03h00, 04h00, 05h00, 06h00, 09h00 and 12h00</description>
    <arm_group_label>volunteers</arm_group_label>
    <other_name>blood sample</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Affiliated or entitled to a social security scheme&#xD;
&#xD;
          -  Volunteers who has received informed information about the study and has co-signed,&#xD;
             with the investigator, a consent to participate in the study.&#xD;
&#xD;
          -  Aged &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Volunteers with a history or morbidities that would contraindicate assessment for&#xD;
             kidney donation according to current recommendations&#xD;
&#xD;
          -  Participation in another clinical research protocol within 3 months prior to inclusion&#xD;
&#xD;
          -  Volunteers having hypersensitivity to Iohexol or one of its excipients&#xD;
&#xD;
          -  Administration of iodinated contrast media in the week prior to inclusion&#xD;
&#xD;
          -  Known history of an immediate allergic reaction or delayed skin reaction to an&#xD;
             iodinated contrast material or any serious doubt about such a history.&#xD;
&#xD;
          -  Pregnancy or breastfeeding in progress&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe MARIAT, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe MARIAT, MD PhD</last_name>
    <phone>(0)477828739</phone>
    <phone_ext>+33</phone_ext>
    <email>christophe.mariat@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carine LABRUYERE, CRA</last_name>
    <phone>(0)477120826</phone>
    <phone_ext>+33</phone_ext>
    <email>carine.labruyere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Christophe MARIAT, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick MISMETTI, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent BERTOLETTI, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine ACCASSAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie MOULIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile DUVILLARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iohexol</keyword>
  <keyword>clearance</keyword>
  <keyword>glomerular filtration flow rate</keyword>
  <keyword>kidney donor</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

